1. Purdue joining pharma’s top settlement list alongside Merck, GSK, and Pfizer — Biosimilars running into more roadblocks in the US — Big Pharma companies pay for exclusive access to UK genetic data — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

How can a company screw up the launch of a drug like Entresto?

Discussion in 'Novartis' started by anonymous, Sep 13, 2019 at 10:04 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This drug should of been a billion dollar drug after a year or 2. Now, many years post-launch, barely hitting goals. Great drug. Terrible company! Only Novartis could screw up such a great drug.
     
  2. anonymous

    anonymous Guest

    We hire poor sales people- good reps tend to always get it done. And we've hired poor management in this division. In Typical Novartis fashion we screw everything up!
     
  3. anonymous

    anonymous Guest

    Management is terrible ... managing like it is the year 2000, metrics, pushing speaker programs, unreal expectations . They don’t think things through they just react ... they don’t listen to what could work because representatives don’t know what they are talking about and complain and make excuses (which don’t get me wrong some really suck) but the general perception is we all do.

    Arrogance and greed take over ... focused on “culture” and not seeing the problem with culture is lack of trust. Trust of management, numbers, people ... it’s all a cluster and why Entresto isn’t doing better. Again behind the 8 ball in acknowledging SGLT 2 IS a competitor until there is so much buzz most novartis reps have no idea about diabetes and the CV risks much less why but hey lets cram a crap ton of information into a 2 day meeting . Oh don’t forget there are problems with syllabus ... training appears then disappears ... let’s contract with managed care a year after launch ... seems like a great idea ... let change the rules mid game ... awesome ... let’s role out a new BV tool that now doesn’t work ... all lumped together ... that’s how Novartis messed it up and continues to do so.
     
  4. anonymous

    anonymous Guest

    Year if the field ! Further my distrust in numbers ... problem with IC2 payouts ... adjustments were made ... nice kept secret except to those that were effected ...